Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3509-3526

  Liu, Li ^a   Liu, Xiaoxia ^a   Xu, Qian ^a   Wu, Ping ^b   Zuo, Xialin ^c   Zhang, Jingjing ^a   Deng, Houliang ^a   Wu, Zhuomin ^a   Ji, Aimin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Chengdu Integrated TCM and Western Medicine Hospital   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gene silencing; Self assembly nanoparticles; siRNA delivery; Tumor targeting

Indexed keywords

ALPHA INTERFERON; CYCLOPEPTIDE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; NANOPARTICLE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; DRUG CARRIER; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG UPTAKE; EMBRYO; ENCAPSULATION; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY; VEGFR2 GENE; ZEBRA FISH; ANIMAL; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; INTRACELLULAR SPACE; METABOLISM; NUDE MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DRUG CARRIERS; GENE SILENCING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SPACE; MICE; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84905263602     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S63717     Document Type: Article

References (49)

1. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000; 101(1): 25-33.
2. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007; 6: 443-453.
3. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007; 6: 556-568.
4. Aliabadi HM, Landry B, Sun C, Tang T, UludaǧH. Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials. 2012; 33: 2546-2569.
5. Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009; 133: 11-17.
6. Pan J, Liu Y, Feng SS. Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond). 2010; 5: 347-360.
7. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464: 1067-1070.
8. Alexis F, Basto P, Levy-Nissenbaum E, et al. HER-2-targeted nanoparticleaffibody bioconjugates for cancer therapy. Chem Med Chem. 2008; 3: 1839-1843.
9. Keenan RM, Callahan JF, Samanen JM, et al. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists. J Med Chem. 1999; 42(4): 545-559.
10. Fisher MJ, Gunn B, Harms CS, et al. Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa. J Med Chem. 1997; 40(13): 2085-2101.
11. Zablocki JA, Miyano M, Garland RB, et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor. J Med Chem. 1993; 36(13): 1811-1819.
12. Egbertson MS, Chang CT, Duggan ME, et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem. 1994; 37(16): 2537-2551.
13. Zablocki JA, Miyano M, Garland RB, et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J Med Chem. 1995; 38(13): 2378-2394.
14. Hutchinson JH, Cook JJ, Brashear KM, et al. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3, 4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. J Med Chem. 1996; 39(23): 4583-4591.
15. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell. 2000; 101(1): 47-56.
16. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science. 2002; 296(5565): 151-155.
17. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci. 2006; 119(19): 3901-3903.
18. Shimaoka M, Xiao T, Liu JH, et al. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 2003; 112(1): 99-111.
19. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10: 9-22.
20. Thairu N, Kiriakidis S, Dawson P, Paleolog E. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis. 2011; 14(3): 223-234.
21. Hanahan D, Weinberg RA. The hall marks of cancer. Cell. 2000; 100(1): 57-70.
22. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004; 94(5): 664-670.
23. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4): 581-611.
24. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem. 2006; 13(16): 1845-1857.
25. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000; 166: 475-480.
26. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86: 353-364.
27. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117: 927-939.
28. Chen S, Liu S, Gong W, et al. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncol Rep. 2013; 29: 260-268.
29. Westerfield M. The Zebrafish Book: A Guide for the Laboratory Use of zebrafish Danio* (Brachydanio) rerio. 4th Ed. [Eugene, Or.]: ZFIN; 2000. Available from: http://zfin. org/zf_info/zfbook/zfbk. html. Accessed July 16, 2014.
30. Subbarao NK, Parente RA, Szoka FC Jr, Nadasdi L, Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry. 1987; 26(11): 2964-2972.
31. Sakurai Y, Hatakeyama H, Sato Y, et al. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials. 2011; 32: 5733-5742.
32. Zhao ZX, Gao SY, Wang JC, et al. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials. 2012; 33: 6793-6807.
33. Gao J, Liu W, Xia Y, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through antiEGFR antibody conjugation by immunoliposomes. Biomaterials. 2011; 32: 3459-3470.
34. Jain N, Wang Y, Jones SK, Hawkett BS, Warr GG. Optimized steric stabilization of aqueous ferrofluids and magnetic nanoparticles. Langmuir. 2010; 26(6): 4465-4472.
35. Hsu SH, Ho TT, Tseng TC. Nanoparticle uptake and gene transfer efficiency for MSCs on chitosan and chitosan-hyaluronan substrates. Biomaterials. 2012; 33: 3639-3650.
36. Thomas M, Klibanov AM. Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol. 2003; 62: 27-34.
37. Green JJ, Chiu E, Leshchiner ES, Shi J, Langer R, Anderson DG. Electrostatic ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary cells. Nano Lett. 2007; 7: 874-879.
38. Arote R, Hwang SK, Lim HT, et al. The therapeutic efficiency of FPPEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model. Biomaterials. 2010; 31: 2435-2445.
39. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003; 24: 1121-1131.
40. Datiles MJ, Johnson EA, McCarty RE. Inhibition of the ATPase activity of the catalytic portion of ATP synthases by cationic amphiphiles. Biochim Biophys Acta. 2008; 1777: 362-368.
41. Bottega R, Epand RM. Inhibition of protein kinase C by cationic amphiphiles. Biochemistry. 1992; 31: 9025-9030.
42. Li Q, Wang J, Shahani S, et al. Biodegradable and photocrosslinkable polyphosphoester hydrogel. Biomaterials. 2006; 27: 1027-1034.
43. Wargelius A, Ellingsen S, Fjose A. Double-stranded RNA induces specific developmental defects in zebrafish embryos. Biochem Biophys Res Commun. 1999; 263: 156-161.
44. Wang L, Zhou JY, Yao JH, Lu DR, Qiao XJ, Jia W. U6 promoter-driven siRNA injection has nonspecific effects in zebrafish. Biochem Biophys Res Commun. 2010; 391: 1363-1368.
45. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008; 60: 1615-1626.
46. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 2008; 26(10): 552-558.
47. Liu P, Yu H, Sun Y, Zhu M, Duan Y. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials. 2012; 33: 4403-4412.
48. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23: 457-462.
49. Marques J, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005; 23: 1399-1405.